ClinicalTrials.gg
RecruitingNCT07107685OASIS²Updated Jun 1, 2026

Prosthetic Joint Infection : Lessons From Deceased Patients in Critical Care.

An observational study in Osteoarticular Infections, Intensive Care Patients and Prosthetic Joint Infection, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris — 14 open to participants now, 15 under way, 3 of them phase 3. Sepsis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
7th of 12
150 · median 160
Started
2025
with 2 others
Observational
12 of 35
5 open now
Primary completion
2026-09
later than 5 of 14 live
Registered
30th of 35
by date

Among the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2025, is one of 12 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 30th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This is an observational, retrospective, multicenter study based on the use of demographic, clinical and biological data from deceased patients admitted between 2018 and 2022 to critical care with a principal or associated diagnosis of joint prosthesis infection.

Data from this study will be combined with that from the OASIS study (APHP241174/ ID-RCB: 2024-A01769-38) concerning osteoarticular sepsis on prosthetic material in critical care of living patients.

The aim of this study is to improve our knowledge of the profile, care trajectories and outcomes of patients hospitalized in critical care in the context of osteoarticular material sepsis.

The results of the study could help identify at-risk populations and improve management strategies for patients with osteoarticular sepsis.

03

Conditions studied

  • Osteoarticular Infections
  • Intensive Care Patients
  • Prosthetic Joint Infection

Browse trials for

Keywords

  • Osteoarticular sepsis
  • sepsis
  • osteoarticular prothetis
  • intensive care
  • critical care
  • prosthetic joint infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critical care patients (intensive care and continuing care), admitted between 2018 and 2022 with a principal or associated diagnosis of joint prosthesis infection, who have since died.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or older.
  • Hospitalization in critical care (intensive care unit or continuing care unit) between 2018 and 2022, lasting at least 48 hours, with a prosthetic joint infection (hip, knee, or shoulder prosthesis infection) as the primary or associated diagnosis.
  • Deceased patient who had not refused data processing.

Exclusion criteria

Exclusion Criteria:

  • Infection involving osteosynthesis material
  • Infection involving spinal instrumentation
  • Patient with multiple infected prostheses
  • Recurrence of prosthetic infection with the same microorganism as a previous episode
  • Patient under legal protection
  • Pregnant or breastfeeding patient
  • Patient deprived of liberty
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • OtherGlobal cohort

    All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.

06

What researchers measure

Primary outcomes

  1. Epidemiological description of deceased patients

    Demographic data, medical history, history of Periprosthetic Joint Infection (timing, diagnosis, surgery, antibiotics), data in intensive care unit (leng of stay, organ failure, drugs and mechanical support, biological data) and outcome (time of death within 2 years after admission to Intensive Care Units).

    Time frame: 2 years

Secondary outcomes

  1. Composite endpoint reflecting poor clinical outcome

    * Mortality, measured in critical care, at 30 days, 1 year and 2 years. * Therapeutic failure at 2 years, defined as mechanical or septic failure. * Functional failure at 2 years, defined as failure to resume walking and usual activities, to return home, or to regain autonomy.

    Time frame: 2 years

  2. Mortality at 2 years

    Time frame: 2 years

  3. Epidemiological description based on the number (n) and proportion (%) of bacterial strains found in samples collected during the operation.

    Special focus on: Gram-positive bacteria (Staphylococcus, Streptococcus, Enterococcus), Gram-negative bacteria (Enterobacteriacea, Pseudmononas), slow-growing bacteria (Cutibacterium, Corynenbacteria), yeasts; resistance mechanisms (meticillin, rifampicin, quinolone, glycopeptide, ESBL, carbapenem).

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Aug 6, 2025
StartActual
Sep 24, 2025
Primary completionEst.
Sep 24, 2026
CompletionEst.
Sep 24, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07107685
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Sep 24, 2025
Primary completion
Sep 24, 2026 (estimated)
Completion
Sep 24, 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Benjamin SOYER, MD, Msc
Contact
benjamin.soyer@aphp.fr
+33 1 49 95 85 15
Benjamin CHOUSTERMAN, MD, PhD
Contact
benjamin.chousterman@aphp.fr
Carine PARE
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion